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Nanoliposomes are new technological developments for the encapsulation and delivery of bioactive 
agents. Incorporation of antitumoral drugs in nanoliposomes has been used to overcome some 
pharmacological disadvantages, like drug toxicity or diminish circulation time of the drug due to rapid 
elimination, having the advantage of being biocompatible and biodegradable [1,2]. 
In this work, a potential antitumoral fluorescent compound, methyl 3-amino-6-(benzo[d]thiazol-2-
ylamino)thieno[3,2-b]pyridine-2-carboxylate 1 [3] (Fig. 1), was evaluated for the in vitro cell growth 
inhibition on three human tumor cell lines, A375-C5 (melanoma), MCF-7 (breast adenocarcinoma) and 
NCI-H460 (non-small cell lung cancer), after a continuous exposure of 48 h, exhibiting low GI50 values 
for all the cell lines tested (3.5-6.4 µM). 
Nanoliposomes were prepared by injection of an 
ethanolic solution of the different lipid mixtures in 
aqueous media under vigorous stirring, above the 
melting transition temperature of the lipids, followed 
by six extrusion cycles. Several lipid formulations 
were tested including phosphatidylcholines, DSPE-
PEG and phosphatidylglycerol at different ratios, with 
or without cholesterol. 
Dynamic light scattering (DLS) measurements indicated that the nanoliposomes with the incorporated 
compound are generally monodisperse and with diameters between 60 nm and 120 nm.  
Compound 1 exhibits fluorescence in non-polar media, while no emission is observed in protic 
solvents (like ethanol and water). It also shows significant fluorescence emission when incorporated in 
nanoliposomes, indicating that it can be transported in the hydrophobic region of the lipid bilayer. 
These results may be important for future drug delivery applications of this potential antitumoral 
compound using nanoliposomes as drug carriers. 
 
Acknowledgements  
This work was funded by FCT-Portugal through CFUM, CQ/UM, Project PTDC/QUI/81238/2006 cofinanced by 
FCT and program FEDER/COMPETE (FCOMP-01-0124-FEDER-007467) and by FCT grants of R. C. Calhelha 
(SFRH/BD/29274/2006) and L. Vale-Silva (SFRH/BPD/29112/2006). 
 
References 
[1] R. Banerjee, J. Biomater. Appl. 16 (2001) 3-21. 
[2] Y. Malam, M. Loizidou, A. M. Seifalian, Trends in Pharmacol. Sci. 30 (2009) 592-599. 
[3] M.-J.R.P. Queiroz, R.C. Calhelha, L. Vale-Silva, E. Pinto, M.S.-J. Nascimento, Eur. J. Med. Chem., accepted 
Sept. 2010. DOI: 10.1016/ejmech.2010.09.030. 
 
  
 
 
N
S
NH2
CO2Me
N
N
S
H
 
        Figure 1 - Structure of compound 1 
